Stockscreener 앱 받기
2.28
10.68%
0.22
시간 외 거래:
2.30
0.02
+0.88%
전일 마감가:
$2.06
열려 있는:
$2.11
하루 거래량:
4.39M
Relative Volume:
1.56
시가총액:
$467.27M
수익:
$12.87M
순이익/손실:
$-114.34M
주가수익비율:
-0.9956
EPS:
-2.29
순현금흐름:
$-79.23M
1주 성능:
+39.88%
1개월 성능:
+10.68%
6개월 성능:
-26.21%
1년 성능:
+34.12%
1일 변동 폭
$2.065
$2.34
1주일 범위
$1.94
$2.63
52주 변동 폭
$1.19
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
TSHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TSHA | 2.28 | 467.27M | 12.87M | -114.34M | -79.23M | -2.29 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts - Benzinga
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript - Insider Monkey
RA Capital Management, L.P. Increases Stake in Taysha Gene Thera - GuruFocus.com
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownWhat's Next? - MarketBeat
Hims & Hers stock falls as Amazon launches Telehealth offering - MSN
Avoro Capital Advisors LLC Increases Stake in Taysha Gene Therap - GuruFocus.com
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Creative Planning Makes New $28,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlight - GuruFocus.com
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... - Yahoo Finance
Taysha Gene Therapies Advances in Rett Syndrome Trials - TipRanks
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene Reports Strong Safety Data, FDA Approval for TSHA-102 Trials; Net Loss Narrows | TSHA Stock News - StockTitan
Taysha Gene Therapies' SWOT analysis: promising Rett syndrome stock faces pivotal year - Investing.com UK
FMR LLC's Strategic Reduction in Taysha Gene Therapies Inc - GuruFocus.com
Neurogene’s Rett Data Draw Optimism Despite Serious Adverse Event - Citeline
Preview: Taysha Gene Therapies's Earnings - Benzinga
JMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Piper Sandler expects Taysha Gene to recover, maintains $7 shares target - Investing.com UK
U.S. Stock market top gainers: BTC Digital surges by 68.60%, Revance Therapeutics climbed by 20.00% in early trading - Business Upturn
Piper Sandler stays bullish on Taysha Gene shares, maintains Overweight rating - Investing.com UK
Taysha Gene Therapies (NASDAQ:TSHA) Given Buy Rating at Needham & Company LLC - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Analyzing Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) - Defense World
Neurogene plummets 35% on gene therapy trial data for Rett syndrome - Seeking Alpha
Taysha Gene Therapies Inc (NASDAQ: TSHA) Gains 5.63% In Early Trade; What Lies Ahead? - Stocks Register
Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.38 - Defense World
Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday - MarketBeat
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 - The Manila Times
Taysha Gene Therapies to Release Third Quarter 2024 - GlobeNewswire
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Taysha Gene Therapies reiterates stock target with positive outlook By Investing.com - Investing.com Canada
TSHATaysha Gene Therapies, Inc. Latest Stock News & Market Updates - StockTitan
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ABEOAbeona Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
SG Americas Securities LLC Purchases Shares of 63,984 Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies' SWOT analysis: promising gene therapy stock faces key catalysts - Investing.com
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress - The Manila Times
Taysha Gene Therapies to Present Biodistribution Data from - GlobeNewswire
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire
Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey
Trading Day Review: Taysha Gene Therapies Inc (TSHA) Loses Momentum, Closing at 1.99 - The Dwinnex
Can you now get a good deal on Taysha Gene Therapies Inc’s shares? - US Post News
Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Produces Clinical Improvements in Swallowing in Phase 1b/2a Trial - CGTLive™
When a Miracle Cure Is Left on the Shelf - Bloomberg
Investing in Taysha Gene Therapies Inc (TSHA): What You Must Know - Knox Daily
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) is looking forward to a strong quarter - SETE News
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):